A SIMPLE KEY FOR HEMGENIX UNVEILED

Number of eligible patients: CDEC mentioned the uncertainty in the amount of individuals with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as obtaining gentle or moderate disease can have a intense bleeding phe